Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...

Incyte Corp (INCY) reports a 24% revenue increase, driven by Jakafi and Opzelura, while navigating regulatory challenges and ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

On Wednesday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $73.93 which represents a slight increase of $0.33 or 0.45% from the prior close of $73.6. The stock opened at $73.6 and ...

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of ...

Fintel reports that on October 30, 2024, B of A Securities upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to ...